Related to this topic: Leaflets | Support | Patient+ | Equipment | Books | Your Experience | Other resources | Glossaries
Print options: Printer friendly version of this leaflet (html)     Other options:  AddThis Social Bookmark Button (what's this?)

PatientPlus articles are written for doctors and so the language can be technical. However, some people find that they add depth to the articles found in the other sections of this website which are written for non-medical people.

Pompe's Glycogen Storage Disease

Synonyms: Glycogen storage disease type II; Acid maltase deficiency

Pompe's disease is one of the glycogen storage disorders. The deficiency of alpha-1,4-glucosidase (acid maltase), a lysosomal enzyme, leads to the accumulation of glycogen in many tissues:

  • In the infantile form, accumulation of glycogen in cardiac muscle leads to cardiac failure.
  • Accumulation may also occur in the liver, which results in hepatomegaly and elevation of hepatic enzymes.
  • Glycogen accumulation in muscle and peripheral nerves causes hypotonia and weakness.
  • Glycogen deposition in blood vessels may result in intracranial aneurysms.
Epidemiology
  • The overall prevalence has been estimated at 1 in 40,000, with 1 in 138,000 for the infantile form and 1 in 57,000 for the adult form.1
  • Infantile and adult forms are inherited as autosomal recessive conditions. The gene has been traced to chromosome 17.2
Presentation
  • Presentation later in life is associated with a less severe form of disease.
  • There is a continuous spectrum between the classic infantile and adult forms.
  • The infantile form presents with hypotonia at anytime after birth, but usually presents at between 4-8 weeks.
  • The adult form usually presents as skeletal and respiratory muscle weakness. The typical age of presentation is 20-40 years.

Symptoms

  • The infantile form may present with feeding and breathing difficulties and dyspnoea.
  • May present with muscle weakness later in childhood.
  • The adult form may have limb-girdle weakness and weakness of respiratory muscles.3

Signs

  • Infantile form:
    • Cardiomegaly and congestive heart failure.
    • Generalised hypotonia, absent or reduced reflexes.
    • Enlarged tongue.
    • Reflexes may be depressed or absent because of glycogen accumulation in spinal motor neurons.
    • Alertness may be impaired.
  • Adult form:
    • Weakness may affect only specific muscle groups, e.g. upper arms, and may be asymmetrical.
    • Limb-girdle weakness is common and respiratory muscle involvement may be prominent.4
Differential Diagnosis
  • Other glycogen storage disorders.
  • Muscular dystrophy: Duchenne muscular dystrophy, or less severe muscular dystrophies for older onset disease.
Investigations
  • Creatine kinase is elevated5
  • Liver function tests: liver failure may occur
  • Acid maltase levels are reduced in fibroblasts2
  • Intracranial aneurysms: may be shown on angiography or magnetic resonance angiography
  • Echocardiography: to assess heart size and degree of left ventricular hypertrophy
  • ECG: Short PR interval and elevated QRS complexes in the infantile form
  • Muscle biopsy: in the evaluation of differential diagnosis of muscle weakness
Management
  • No specific treatment exists and current management is focused on supportive care.
  • Diet therapy may be helpful: a high-protein, low carbohydrate diet may be beneficial.6
  • Recombinant human acid alpha-glucosidase enzyme therapy has been shown to improve cardiac and skeletal muscle function.7,8
  • Gene therapy remains a potentially effective treatment for the future.9
Complications
  • In the infantile form, cardiomegaly and congestive heart failure lead to death.
  • Cardiomegaly with progressive obstruction to left ventricular outflow is a major cause of mortality.
  • Weakness of ventilatory muscles increases the risk of pneumonia.
  • The adult form manifests with dystrophy and respiratory muscle weakness.
  • In the adult form, intracranial aneurysms present the greatest complication.
Prognosis
  • The infantile form usually is fatal, with most deaths occurring within 1 year of birth.10
  • Later clinical onset usually corresponds with more benign symptoms and disease course.
  • The adult form is not necessarily fatal, but complications such as rupture of an aneurysm or respiratory failure may cause significant morbidity or mortality.


Document References
  1. Ausems MG, Verbiest J, Hermans MP, et al; Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. Eur J Hum Genet. 1999 Sep;7(6):713-6. [abstract]
  2. Online Mendelian Inheritance in Man; Glycogen Storage Disease II.
  3. Sivak ED, Salanga VD, Wilbourn AJ, et al; Adult-onset acid maltase deficiency presenting as diaphragmatic paralysis. Ann Neurol. 1981 Jun;9(6):613-5. [abstract]
  4. Trend PS, Wiles CM, Spencer GT, et al; Acid maltase deficiency in adults. Diagnosis and management in five cases. Brain. 1985 Dec;108 ( Pt 4):845-60. [abstract]
  5. Ausems MG, Lochman P, van Diggelen OP, et al; A diagnostic protocol for adult-onset glycogen storage disease type II. Neurology. 1999 Mar 10;52(4):851-3. [abstract]
  6. Isaacs H, Savage N, Badenhorst M, et al; Acid maltase deficiency: a case study and review of the pathophysiological changes and proposed therapeutic measures. J Neurol Neurosurg Psychiatry. 1986 Sep;49(9):1011-8. [abstract]
  7. Amalfitano A, Bengur AR, Morse RP, et al; Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med. 2001 Mar-Apr;3(2):132-8. [abstract]
  8. Brady RO, Schiffmann R; Enzyme-replacement therapy for metabolic storage disorders. Lancet Neurol. 2004 Dec;3(12):752-6. [abstract]
  9. Coutelle C, Themis M, Waddington SN, et al; Gene therapy progress and prospects: fetal gene therapy--first proofs of concept--some adverse effects.; Gene Ther. 2005 Nov;12(22):1601-7. [abstract]
  10. van den Hout HM, Hop W, van Diggelen OP, et al; The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics. 2003 Aug;112(2):332-40. [abstract]

Internet and Further Reading Acknowledgements EMIS is grateful to Dr Colin Tidy for writing this article. The final copy has passed scrutiny by the independent Mentor GP reviewing team. ©EMIS 2007.
DocID: 2633
Document Version: 20
DocRef: bgp1421
Last Updated: 15 May 2007
Review Date: 14 May 2009




















Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.

Advertise on this site










Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.

Advertise on this site


PS - Health and Poverty

Perhaps the biggest cause of ill health in the world is poverty. Help to Make Poverty History. For example, why not lend some of your money to disadvantaged communities to enable them to trade their way out of poverty through schemes such as Shared Interest.

See also MAKEPOVERTYHISTORY North East for details and links to campaigns against poverty.

^ Top of Page